IDSA 2025年复杂性尿路感染抗菌治疗选择指南
美国感染病学会(IDSA)发布2025年复杂性尿路感染(cUTI)抗菌治疗选择指南,基于2008年以来系统综述及2000年以来耐药预测因素文献,采用GRADE方法评级。指南建议按病情严重程度和抗菌药物管理分层,优先选择首选经验性抗生素,并用4步流程指导个体化选药,最终依据尿培养结果转为针对性治疗。
要点
- 经验性治疗优先选首选方案而非替代方案,并按病情严重程度与抗菌药物管理分层。
- 选药采用4步流程:评估病情、评估耐药风险因素、评估其他个体因素、脓毒症患者参考本地药敏谱。
- 获得尿培养结果后应转为针对性窄谱有效治疗。
核心结论
- 多种获批治疗cUTI的抗生素类别在随机对照试验中疗效相似。
- 细菌耐药流行情况不断变化且将有新抗生素问世,指南据此提供经验性选药建议以帮助临床决策。
研究设计与样本
- IDSA指南小组基于系统文献综述制定推荐,综述聚焦获批用于cUTI的抗生素类别的比较获益与危害,纳入2008年起的文献。
- 耐药预测因素综述纳入2000年以来鉴定的参考文献。
- 推荐采用GRADE方法对证据确定性和推荐强度进行标准化评级。
主要发现
- 指南建议在首选经验性抗生素方案中选择,而非替代方案,并按病情严重程度和抗菌药物管理考虑进行分层。
- 指南提出4步选药流程:(1)评估病情严重程度以初步排序抗生素;(2)考虑耐药尿路病原体的患者特异性危险因素以优化覆盖;(3)评估其他患者特异性因素以降低不良事件风险;(4)脓毒症患者如具备本地药敏谱则参考之。
- 指南建议依据尿培养结果选择针对性窄谱的确定性有效治疗。
临床怎么用
- 在cUTI经验性选药时按首选方案、病情严重程度和抗菌药物管理分层决策。
- 按4步流程个体化选药,脓毒症患者尽可能参考本地药敏谱。
- 尿培养结果回报后及时降阶梯为针对性窄谱治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: These recommendations address the empiric choice of antibiotics in suspected complicated urinary tract infection (cUTI). Issues to balance include the need for appropriate initial empiric antimicrobial therapy, the patient's severity of illness, and antimicrobial stewardship concerns. METHODS: The panel's recommendations are based upon evidence derived from systematic literature reviews that focused on comparative benefits and harms of classes of antibiotics approved for cUTI, starting with publications from 2008 onwards, and our review of predictors of resistance in uropathogens included references identified since 2000. These recommendations adhere to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. RESULTS: The guidelines panel suggests initially selecting among preferred empiric antibiotic choices rather than alternative options, stratified for the patient's severity of illness and antimicrobial stewardship considerations. When choosing among these antibiotics for a specific patient, the guideline panel suggests a 4-step process to account for changing resistance patterns and individualized patient needs. The steps are: (1) assess the severity of illness (for initial prioritization of antibiotics), (2) consider patient-specific risk factors for resistant uropathogens (for optimization of coverage), (3) evaluate other patient-specific considerations (to reduce the risk of adverse events), and (4) for patients with sepsis, consult a relevant local antibiogram if available (to further improve the likelihood of giving appropriate empiric therapy). Lastly, the guideline panel suggests selecting definitive effective therapy with a targeted spectrum based on the result of the urine culture. CONCLUSIONS: Many of the classes of antibiotics approved to treat cUTI demonstrate similar efficacy as other classes of antibiotics in randomized controlled trials. Bacterial resistance prevalence is always changing, and new antibiotics will be developed. In this context, the guidelines panel provides recommendations for choosing empiric antibiotic therapy for cUTI that will help clinicians decide among available antibiotic options at the point of care.
引用
- Trautner BW, Cortés-Penfield NW, Gupta K, et al. Clinical Practice Guidelines by Infectious Diseases Society of America: 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections-Selection of Antibiotic Therapy for Complicated Urinary Tract Infections. Clin Infect Dis. 2026. PMID: 41419213. doi:10.1093/cid/ciaf460
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。